Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
mRNA cleavage
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "mRNA cleavage" in MCE Product Catalog:
15
Category:
Infection Microorganisms Antibiotics Disease Research Antibacterial Disease Research Fields Other Antibiotics
Target:
Cat. No.: HY-153491
CAS No.: 2097587-83-0
Synonyms: ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx
Target:
Research Areas:
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
Synonyms: ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium
Target:
Research Areas:
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) sodium is a GalNAc-modified antisense oligonucleotide. Olezarsen sodium binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen sodium reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen sodium is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
Cat. No.: HY-145425
CAS No.: 2771006-54-1
Research Areas:
PAIR2 is a highly selective inhibitor targeting the kinase domain of human IRE1α, with a Ki value of 8.8 nM against human IRE1α. PAIR2 fully occupies the ATP-binding site of the IRE1α kinase domain, partially antagonizes the ribonuclease activity of IRE1α, specifically inhibits regulated IRE1α-dependent decay (RIDD) and its mediated substrate cleavage, while preserving the splicing function of Xbp1 mRNA. PAIR2 also promotes the differentiation of B cells into plasma cells, blocks IRE1α-induced cell apoptosis, and restores the expression of Fgfr2 mRNA in AT2 cells. PAIR2 effectively reaches a steady-state concentration in the lung tissues of Mus musculus, and serves as an important tool for investigating the function of the IRE1α signaling pathway in diseases such as pulmonary fibrosis .
Cat. No.: HY-115590
CAS No.: 1902983-63-4
JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 (IC50 = 0.5 nM). JP11646 is freely reversible and ATP non-competitive. JP-11646 results in a decrease of PIM1, 2, and 3 mRNA. JP-11646 can effectively inhibit cell viability in small cell lung cancer (SCLC) and large cell neuroendocrine carcinomas of the lung (LCNEC). JP-11646 can cause a decrease in p-4EBP-1 protein, increasing the cleavage of caspases while decreasing caspase-3. JP-11646 induces apoptosis or necroptosis in cells. JP-11646 leads to reductions in MYC paralogs. JP-11646 can be used for the study of SCLC, LCNEC, human acute leukemia (AML), multiple myeloma (MM), and triple-negative breast cancer (TNBC) .
Cat. No.: HY-177646
CAS No.: 2572991-83-2
Synonyms: ALN-APP
Research Areas:
Mivelsiran (ALN-APP) is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran can be used for research on early-onset Alzheimer's disease .
Cat. No.: HY-177646A
Synonyms: ALN-APP sodium
Research Areas:
Mivelsiran (ALN-APP) sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
Cat. No.: HY-174499
Cas9 Nickase D10A mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double-stranded break at the target site, Cas9 nickase creates a single-stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.
Target:
Research Areas:
Ara-ATP is an ATP-competitive poly (A) polymerase (poly (A) polymerase) inhibitor with a Ki value of 4 μM for the chromatin-bound form and a Ki value of 60 μM for the nucleoplasmic (free) form. Ara-ATP blocks pre-mRNA 3' end processing by inhibiting endonucleolytic cleavage, poly (A) addition, and the formation of cleavage and polyadenylation-specific RNA-protein complexes. Ara-ATP selectively inhibits initial polyadenylation rather than poly (A) elongation. Ara-ATP is used in the study of viral infections .
Cat. No.: HY-103248R
CAS No.: 606-58-6
Synonyms: Vengicide (Standard)
Target:
Cat. No.: HY-153805
CAS No.: 1373391-77-5
Target:
Research Areas:
Z-NCTS is a small molecule that binds to mismatched RNA, recognizes the 5'-r (XGG)-3'/5'-r (XGG)-3' sequence, and acts as an RNA molecular glue. Z-NCTS induces the formation of tertiary structures in ribozymes and activates their RNA cleavage activity. As an RNA molecular glue, Z-NCTS enables small molecule-based strategies for regulating RNA structure and function. Z-NCTS binds to d (CGG)/d (CGG) double-stranded DNA, recognizes four guanine bases via hydrogen bonding, and stabilizes the double-stranded DNA. Z-NCTS binds to r (GGG)/r (GGG) double-stranded RNA and enhances the thermodynamic stability of the RNA duplex. Z-NCTS acts as a translation inhibitor by inducing the formation of stable hairpin structures in the 5'-UTR region of engineered mRNA, thereby blocking ribosomal access to the binding site .
Cat. No.: HY-P703322
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CPSF3; mRNA 3'-End-Processing Endonuclease CPSF-73; cleavage And Polyadenylation Specific Factor 3; YSH1; CPSF73; cleavage And Polyadenylation Specific Factor 3, 73kD Subunit; cleavage And Polyadenylation Specificity Factor Subunit 3; CPSF 73 KDa Subunit
Species:
Human
Source:
E. coli
Cat. No.: HY-P86815
Synonyms: ATP/GTP binding protein antibody; cleavage and polyadenylation factor I subunit 1 antibody; CLP 1 antibody; clp1 antibody; CLP1 cleavage and polyadenylation factor I subunit homolog antibody; CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae) antibody; CLP1, yeast, homolog of antibody; CLP1_HUMAN antibody; hClp1 antibody; Homolog of yeast CFIA subunit Clp1p antibody; ATP/GTP binding protein antibody; cleavage and polyadenylation factor I subunit 1 antibody; CLP 1 antibody; clp1 antibody; CLP1 cleavage and polyadenylation factor I subunit homolog antibody; CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae) antibody; CLP1, yeast, homolog of antibody; CLP1_HUMAN antibody; hClp1 antibody; Homolog of yeast CFIA subunit Clp1p antibody; Polyadenylation factor Clp1 antibody; Polynucleotide kinase Clp1 antibody; Polyribonucleotide 5' hydroxyl kinase Clp1 antibody; Polyribonucleotide 5''-hydroxyl-kinase Clp1 antibody; Pre mRNA cleavage complex II protein Clp1 antibody; Pre-mRNA cleavage complex II protein Clp1 antibody;
Cat. No.: HY-134031A
CAS No.: 71997-34-7
Target:
Research Areas:
Ara-ATP trisodium is an ATP-competitive poly (A) polymerase (poly (A) polymerase) inhibitor with a Ki value of 4 μM for the chromatin-bound form and a Ki value of 60 μM for the nucleoplasmic (free) form. Ara-ATP trisodium blocks pre-mRNA 3' end processing by inhibiting endonucleolytic cleavage, poly (A) addition, and the formation of cleavage and polyadenylation-specific RNA-protein complexes. Ara-ATP trisodium selectively inhibits initial polyadenylation rather than poly (A) elongation. Ara-ATP trisodium is used in the study of viral infections .
Cat. No.: HY-P86821
Synonyms: cleavage and polyadenylation specific factor 3 73kDa antibody; cleavage and polyadenylation specificity factor 73 kDa subunit antibody; cleavage and polyadenylation specificity factor subunit 3 antibody; CPSF 73 antibody; CPSF 73 kDa subunit antibody; CPSF antibody; CPSF-73 antibody; cpsf3 antibody; CPSF3_HUMAN antibody; CPSF73 antibody; cleavage and polyadenylation specific factor 3 73kDa antibody; cleavage and polyadenylation specificity factor 73 kDa subunit antibody; cleavage and polyadenylation specificity factor subunit 3 antibody; CPSF 73 antibody; CPSF 73 kDa subunit antibody; CPSF antibody; CPSF-73 antibody; cpsf3 antibody; CPSF3_HUMAN antibody; CPSF73 antibody; mRNA 3''-end-processing endonuclease CPSF-73 antibody; YSH1 antibody;
Cat. No.: HY-189278
KRAS-IN-64 is a KRAS inhibitor that inhibits KRAS translation by binding to and stabilizing the G-quadruplex in the 5'-UTR of KRAS mRNA, exhibits antiproliferative activity in KRAS-mutant cancer cells, and induces cell cycle arrest, non-apoptotic cell death, and PARP cleavage-mediated apoptosis (apoptosis). KRAS-IN-64 can be used for research on pancreatic cancer .
Cat. No.: HY-147262
Research Areas:
Etedesiran is a component of the AOC drug Delpacibart etedesiran (HY-177565), formed by the reaction of an siRNA that induces cleavage of mRNA encoding myotonic dystrophy protein kinase (MTPK or DMPK) with SMCC linker (HY-42360). Etedesiran carries a maleimide group at its terminus, which can react with cysteine or lysine and is used for the synthesis of AOC drugs. Etedesiran is applicable to research related to myotonic dystrophy type 1 .
Cat. No.: HY-177646C
Target:
Research Areas:
FAM labled Mivelsiran (ALN-APP) sodiumis a FAM labled Mivelsiran sodium. Mivelsiran sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
